Trials / Completed
CompletedNCT00362102
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
A Multi-center, Open Label, Non-randomized, Phase II Study to Assess the Activity and Safety of Cetuximab Plus Irinotecan in Subjects With EGFR-detectable Metastatic Colorectal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease to irinotecan-based chemotherapy and who have failed (progressive disease or intolerance) previous oxaliplatin-based and fluoropyrimidine-based chemotherapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetuximab |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2006-08-09
- Last updated
- 2016-11-22
Source: ClinicalTrials.gov record NCT00362102. Inclusion in this directory is not an endorsement.